InstalabLoading...
InstalabLoading...
Your body produces more IgA (immunoglobulin A) than any other type of antibody. Most of it lines your gut, lungs, and nasal passages, acting as a first barrier between the outside world and your bloodstream. The amount circulating in your blood reflects how well that barrier system is functioning. A level that is too low leaves you vulnerable to infections and autoimmune conditions. A level that is persistently elevated can signal kidney disease, chronic immune activation, or other conditions that deserve investigation.
What makes this test useful is that it catches problems hiding behind normal results on a standard blood count or metabolic panel. You can have completely normal kidney function numbers and still be silently depositing abnormal IgA in your kidneys. You can have a normal immune cell count and still lack the mucosal antibody protection your body depends on every day.
IgA exists in two forms. The version in your blood is mostly a single molecule (called monomeric IgA) produced by a type of white blood cell known as a plasma cell. The version coating your gut lining, saliva, tears, and airways is a doubled-up molecule (dimeric IgA) joined with a protective wrapper called the secretory component. This secretory form is your mucosal surfaces' primary defense system.
In your gut, secretory IgA does not just fight invaders. It shapes which bacteria thrive and which are kept in check. Research shows IgA actively sculpts and stabilizes your gut microbial communities, binding to bacteria through sugar molecules on its surface and on theirs. When IgA is absent, specific gut bacteria escape into the bloodstream more easily, triggering system-wide immune activation that would not occur with a healthy mucosal barrier.
IgA also plays a front-line role in fighting infections. During SARS-CoV-2 infection, IgA dominated the early neutralizing antibody response, peaking in the blood around the third week and correlating more strongly with virus neutralization than IgG antibodies. This response fades faster in blood but persists longer in saliva, reflecting IgA's role as a rapid-response defender at mucosal surfaces.
Selective IgA deficiency is the most common primary immune deficiency, defined by very low or undetectable serum IgA with normal levels of other antibodies (IgG and IgM). Many people with this condition never develop symptoms, but a significant fraction experience recurrent respiratory and gastrointestinal infections, allergies, and autoimmune diseases.
Research in IgA-deficient individuals shows that losing mucosal IgA destabilizes the relationship between your immune system and your gut bacteria. Without IgA to keep commensal microbes in their place, more bacteria cross into the bloodstream. The body responds by producing elevated IgG antibodies against these gut bacteria, along with higher levels of inflammatory signaling molecules and increased activation of T cells. This is not a theoretical concern; it is a measurable shift toward systemic immune dysregulation.
IgA deficiency also affects the accuracy of other lab tests. The most relevant example is celiac disease screening: the standard first-line test (tTG-IgA, tissue transglutaminase IgA) relies on your body making enough IgA to detect. If you are IgA-deficient, a negative tTG-IgA result is meaningless, and your doctor needs to use IgG-based tests instead. This is why celiac guidelines recommend measuring total IgA alongside tTG-IgA.
IgA nephropathy (often abbreviated IgAN) is the most common form of primary kidney inflammation worldwide. It occurs when abnormally shaped IgA molecules, specifically a variant called galactose-deficient IgA1 (Gd-IgA1, meaning IgA1 that is missing a key sugar called galactose), form immune complexes that deposit in the kidney's filtering units. Over years to decades, this triggers scarring and progressive loss of kidney function.
The disease follows what researchers call a "four-hit" model. First, the body overproduces Gd-IgA1. Second, the immune system makes antibodies against these abnormal IgA molecules. Third, those antibodies bind to Gd-IgA1, forming circulating immune complexes. Fourth, the complexes lodge in the kidney, activating the complement system (a set of immune proteins that amplify inflammation) and driving tissue damage.
Total serum IgA can be elevated in IgA nephropathy, but a normal IgA level does not rule it out. The disease depends on the quality of IgA (its sugar-coating pattern), not just the quantity. Genetic studies involving nearly 39,000 people have identified over 30 risk locations in the genome linked to IgA nephropathy, many of which overlap with genes that control IgA production and regulation. These same analyses show that genetically higher serum IgA levels increase the risk of developing IgA nephropathy.
IgA nephropathy is not always a slow, benign condition. A large UK registry of 2,299 people with biopsy-confirmed IgA nephropathy found that those with time-averaged proteinuria (protein in the urine, averaged over multiple readings) of 0.88 grams per gram or higher had very high rates of kidney failure within 10 years. Even people with levels previously considered "low risk," between 0.44 and 0.88 g/g, still had about a 30% chance of kidney failure over the same period.
A Swedish nationwide study comparing over 3,000 IgA nephropathy cases to matched controls found about a 6-year reduction in life expectancy and roughly 1.5 times the mortality rate of the general population. In a US cohort from Kaiser Permanente, 36% of IgA nephropathy patients reached a 50% decline in kidney filtration rate, kidney failure, or death within a median follow-up of just 2.7 years. These numbers make clear that early detection and aggressive proteinuria management matter enormously.
IgA vasculitis (formerly called Henoch-Schönlein purpura) is a related condition where IgA-containing immune complexes deposit in small blood vessels instead of (or in addition to) the kidneys. It causes a characteristic rash of raised, reddish-purple spots you can feel on the skin (called palpable purpura), joint pain, abdominal pain, and sometimes kidney inflammation. The underlying mechanism involves the same Gd-IgA1 and anti-Gd-IgA1 antibody pathways seen in IgA nephropathy. In children, older age at onset, reduced kidney filtration rate, and kidney biopsy showing crescent-shaped inflammatory lesions predict worse outcomes.
Total IgA plays an essential supporting role in celiac disease diagnosis. The recommended first-line screen is tTG-IgA (tissue transglutaminase IgA antibody), which has a sensitivity of roughly 91 to 96% and specificity of 99 to 100% in mixed adult and pediatric populations. But this test fails in people who are IgA-deficient, producing false negatives. Measuring total IgA at the same time catches this problem immediately.
For children under 2 years, tTG-IgA remains the best single test, but adding DGP-IgG (deamidated gliadin peptide IgG) modestly improves sensitivity and catches early cases that tTG alone misses. Multiplex panels that simultaneously measure tTG-IgA and total IgA streamline the first-line workup and accurately detect both celiac disease and IgA deficiency in a single draw. Celiac screening is recommended for first-degree relatives of celiac patients, people with type 1 diabetes, autoimmune thyroid disease, Down syndrome, and several other high-risk conditions.
Standard clinical laboratories report total serum IgA using methods that measure how much light a protein solution scatters or absorbs (called nephelometry or turbidimetry). Reference ranges vary modestly between labs and assay platforms, so always compare your results within the same laboratory over time. The following ranges represent typical adult values used in clinical practice.
| Tier | Range (mg/dL) | What It Suggests |
|---|---|---|
| Very Low | Below 7 | Selective IgA deficiency if IgG and IgM are normal; requires IgG-based tests for celiac and other IgA-dependent screens |
| Low | 7 to 69 | Partial IgA deficiency; may increase infection susceptibility and affect celiac serology accuracy |
| Normal | 70 to 400 | Typical adult range; does not rule out IgA nephropathy or other IgA-mediated conditions |
| Elevated | Above 400 | May suggest chronic immune activation, IgA nephropathy, liver disease, or chronic infection; warrants further investigation |
These ranges are for adults and may differ for children, whose IgA levels rise gradually from birth through adolescence. IgA levels also show marked individuality, meaning your personal baseline may sit comfortably at 90 mg/dL while someone else's normal is 300 mg/dL. A single reading within the reference range tells you less than your trend over time.
Serum IgA has low within-person biological variation, meaning a well-timed, properly collected sample is fairly reproducible. However, several factors can temporarily shift your reading or make it harder to interpret.
A single IgA measurement gives you a snapshot. Two or more readings over time give you a story. Research on immunoglobulin biological variation in 12 healthy adults found that IgA has such strong individuality that population reference ranges are much less useful than your personal trend. A shift of more than about 8 to 10% from your own baseline is likely to reflect a real biological change rather than random lab variability.
Get a baseline reading when you are healthy, not during an acute illness or within a few weeks of vaccination. If you are tracking IgA because of a known condition like IgA nephropathy, testing every 3 to 6 months alongside kidney function markers (creatinine, eGFR, urine protein) provides the most useful trajectory. For general immune monitoring, annual testing is reasonable, with more frequent checks if you notice recurrent infections or if other immune markers shift.
Always retest at the same laboratory. Different assay platforms can give slightly different numbers for the same sample, and switching labs introduces noise that obscures real trends.
Evidence-backed interventions that affect your Total IgA level
IgA is best interpreted alongside these tests.